Anti-Hu Tomm34 Purified

Anti-Hu Tomm34 Purified
Regulatory status
RUO
Antigen
Tomm34
Clone
Tomm34-4.1
Format
Purified
Reactivity
Human
Application
Variant
0.1 mg
11-891-C100
In stock
180.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD
Product details
Description
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody Tomm34-4.1 recognizes an epitope within TPR2 domain of human Tomm34 protein.
Application
Reactivity
Human
Immunogen
Recombinant human Tomm34
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on the label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
URCC3, HTOM34P
Antigen description
Tomm34 (translocase of the outer mitochondrial membrane 34) is an additional component of the cellular chaperone system involved in protein folding. As the name suggests, Tomm34 was initially identified as being involved in mitochondrial protein processing. Subsequent studies have shown that Tomm34 interacts with both Hsp70 and Hsp90 and modifies their protein folding activities. In cancer, high levels of Tomm34 have been reported in bladder, colorectal and breast cancers compared to their normal tissue counterparts. In these cancers, Tomm34 promotes colorectal cancer cell growth and is a biomarker of poor outcome in early invasive breast cancer and bladder cancer. As a tumour-associated protein, Tomm34 peptide vaccination is under investigation as a therapeutic option for colorectal cancer, with significant Tomm34 cytotoxic T-lymphocyte (CTL) response observed.
Entrez Gene ID 10953
UniProt ID Q15785

Product specific references:

Müller P, Coates PJ, Nenutil R, Trčka F, Hrstka R, Chovanec J, Brychtová V, Vojtěšek B: Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. J Ovarian Res. 2019 Mar 27;12(1):30.
PubMed
Variant
0.1 mg
11-891-C100
In stock
180.00 USD
Variant
0.1 mg
11-261-C100
In stock
180.00 USD